Format

Send to

Choose Destination
J Clin Oncol. 1994 Jan;12(1):155-8.

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.

Author information

1
Geisinger Clinical Oncology Program, Danville, PA.

Erratum in

  • J Clin Oncol 1996 Aug;14(8):2411.

Abstract

PURPOSE:

To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer.

PATIENTS AND METHODS:

A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study.

RESULTS:

Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot-flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05).

CONCLUSION:

Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

PMID:
8270972
DOI:
10.1200/JCO.1994.12.1.155
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center